Teicoplanin (Teicoplaninum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Glycopeptides

Included in the formulation
  • Orthocid
    powder inwards w / m in / in 
    KRASFARMA, JSC     Russia
  • Targcid®
    lyophilizate
    Aventis Pharma Limited     United Kingdom
  • Teicoplanin
    lyophilizate inwards w / m in / in 
    JODAS EKSPOIM, LLC     Russia
    • АТХ:

    J.01.X.A.02   Teicoplanin

    Pharmacodynamics:

    The glycopeptide antibiotic disrupts the synthesis of the cell wall by blocking the formation of the bacterial membrane by binding to the acyl-D-alanyl-D-alanine mucopeptide, resulting in the formation of spheroplasts.

    It is active against staphylococci, streptococci, micrococci, enterococci, corynebacteria, as well as peptococci and gram-positive anaerobes.

    Pharmacokinetics:

    After parenteral use, bioavailability is 90%. The connection with plasma proteins is 95%.

    Metabolism in the liver.

    The half-life is 150 hours. Elimination by the kidneys.

    Indications:

    It is used for the treatment of infectious and inflammatory diseases of respiratory and urinary tracts, musculoskeletal and gastrointestinal system, septicemia, peritonitis, endocarditis, pseudomembranous colitis caused by Clostridium difficile. Used to prevent postoperative infections in orthopedics and dentistry.

    ICD-10

    IX.I30-I52.I33   Acute and subacute endocarditis

    X.J00-J06.J06   Acute upper respiratory tract infections of multiple and unspecified sites

    X.J20-J22.J22   Acute respiratory infection of lower respiratory tract, unspecified

    XI.K65-K67.K65   Peritonitis

    XII.L00-L08.L08.9   Local infection of skin and subcutaneous tissue, unspecified

    XIII.M00-M03   Infectious arthropathy

    XIII.M60-M63.M60.0   Infectious myositis

    XIII.M65-M68.M65   Synovitis and tenosynovitis

    XIII.M65-M68.M65.0   Abscess of the tendon sheath

    XIII.M70-M79.M71.0   Abscess of synovial bag

    XIII.M70-M79.M71.1   Other infectious bursitis

    XIV.N30-N39.N39.0   Urinary tract infection without established localization

    Contraindications:

    Individual intolerance.

    Carefully:

    Renal insufficiency, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. It is used with caution during pregnancy and lactation in cases where the intended benefit exceeds the risk to the fetus and newborn.

    Dosing and Administration:

    Use in children

    Up to 2 months: 16 mg / kg intravenously drip for 30 minutes, then 8 mg / kg once a day.

    From 2 months to 16 years: 10 mg / kg intravenously 3 times at intervals of 12 hours, then 6-10 mg / kg intravenously or intramuscularly once a day.

    Adults

    Intravenous by 400 mg 1-2 times a day for 1-3 days, then 200-400 mg per day intravenously or intramuscularly.

    The highest daily dose: 800 mg.

    The highest single dose: 400 mg.

    Side effects:

    Central and peripheral nervous system: headache, dizziness, unsteadiness of gait.

    Respiratory system: bronchospasm.

    Hemopoietic system: leukopenia, neutropenia, agranulocytosis, thrombocytopenia, eosinophilia.

    The cardiovascular system: hyperemia of the face, sensation of hot flashes, thrombophlebitis with intravenous injection.

    Digestive system: nausea, vomiting, diarrhea, increased levels of alkaline phosphatase and liver transaminases.

    Dermatological reactions: exfoliative dermatitis, toxic skin necrosis, Stevens-Johnson syndrome, abscess at the injection site.

    Sense organs: tinnitus, hearing loss.

    Urinary system: renal failure.

    Reproductive system: Candida colpitis.

    Allergic reactions.

    Overdose:

    Cases of overdose are not described.

    Treatment is symptomatic. It is not removed by hemodialysis.

    Interaction:

    When used simultaneously with aminoglycosides, amphotericin B, furosemide and cyclosporine increases the risk of oto- and nephrotoxic effects.

    Special instructions:

    Monitoring of liver and kidney function, hearing and hematopoiesis.

    In the treatment it is not recommended to drive vehicles and work with moving mechanisms.

    Instructions
    Up